Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Levocarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.95 |
| ▸ | CPT2 | P23786 | 2/20 | 0.59 |
| ▸ | CPT1A | P50416 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CRAT | P43155 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Carnitine SCHEMBL6855781 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL9633322 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL10631240 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL10435820 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL357560 | 1.00 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL10633747 | 0.98 | SLC22A16 (0.91) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL21970 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL21971 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL1813524 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600953-B2 | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-04-14 | — | — | US | claimed |
| EP-4687486-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4687485-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| WO-2025224069-A1 | CO-CRYSTALS OF FINERENONE, PECAVAPTAN, AND SGLT2 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-30 | — | — | WO | claimed |
| US-12378529-B2 | Method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents | GENEX HEALTH CO., LTD (CN) | 2025-08-05 | — | — | US | claimed |
| CN-119020290-B | Serum replacement, culture medium and application thereof in tumor organoid culture | 山东伯桢生物科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119345175-A | Pharmaceutical composition of fused tricyclic gamma-amino acid derivative | 海思科医药集团股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20250019644-A1 | Quantitatively Mapping Amino Acid Properties (QMAP) Cell Culture Media | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-01-16 | — | — | US | claimed |
| CN-119279086-A | By using 25-OH-VD3Feed composition for improving reproductive performance of sows and preparation method thereof | 山东海能生物工程有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-119286765-A | Organoid basal medium and method for maintaining and promoting organoid growth | 山东伯桢生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-1244575-A | Making process of slimming health beer | WANG BAIHUA (CN) | 2000-02-16 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| CN-1162018-A | Enzymatic preparation of L-carnitine | JIANGSU PROV MICROBIAL INST (CN) | 1997-10-15 | — | — | CN | claimed |
| EP-0497834-A1 | CARNITINE SUPPLEMENTED CAT FISH DIET | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-08-12 | — | — | EP | claimed |
| EP-0252030-B1 | DERIVATIVES OF L-AMINO ACYL L-CARNITINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS HAVING HEPATOPROTECTING ACTIVITY CONTAINING SAME | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-06-17 | — | — | EP | claimed |
| US-5030657-A | Fat reduction, ammonia resistance | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-07-09 | — | — | US | claimed |
| WO-1991005554-A1 | CARNITINE SUPPLEMENTED CAT FISH DIET | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-05-02 | — | — | WO | claimed |
| US-4933490-A | Process for the preparation of L(-)carnitine hydrochloride and of L(-)carnitine inner salt | ISOM S.P.A. (IT) | 1990-06-12 | — | — | US | claimed |
| EP-0252030-A2 | Derivatives of L-amino acyl L-carnitine, process for their preparation and pharmaceutical compositions having hepatoprotecting activity containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1988-01-07 | — | — | EP | claimed |
| US-3949087-A | CARNITINE CHLORIDE | LABAZ (FR) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600953-B2 | Compositions and method for establishing organoid cultures from cryogenically preserved tissue | BMP4, DSP, WNT3A | HRH1 3329/4885CA2 1828/4885SLC22A16 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.